波士顿科学Boston Scientific Corporation（BSX）2025年年度报告「NYSE」（英文版）（144页）.pdf

1、2025 Annual ReportDear Stockholders:In 2025,Boston Scientific continued to deliver relentless innovation and enduring growth.Propelled by the talent and dedication of our global teams,we built on our track record of consistent financial performance to achieve another outstanding year.Our results kee

2、p us on course toward our goal of consistently being the highest-performing large-cap company in MedTech.To that end,our focus remains on strengthening our innovation ecosystem with a differentiated product pipeline designed to support sustainable growth over the long term.We had many notable develo

3、pments to be proud of in 2025.Of all our achievements,one stands above the rest:We helped improve the lives of more than 48 million patients around the world.For this and all our accomplishments,I extend my deepest thanks to our 59,000 values-driven employees,who live out our purpose of“advancing sc

4、ience for life”every day.Their skills,dedication and winning spirit are what make Boston Scientific such a remarkable company.2025 ResultsOur full-year net sales were$20 billion a significant milestone for Boston Scientific.This represents growth of 19.9 percent on a reported basis,19.2 percent on a

5、n operational1 basis and 15.8 percent on an organic2basis compared to 2024.Our worldwide performance is reflected in strong operational growth across our regions.Compared to 2024,we grew operational net sales by 26 percent in the United States,3.2 percent in Europe,Middle East and Africa(EMEA),14.5

6、percent in Asia Pacific(APAC)and 10.7 percent in Latin America and Canada (LACA).Net sales in Emerging Markets3 countries grew 11.6 percent on an operational basis compared to 2024.Our full-year adjusted operating margin4 was 28 percent with adjusted earnings per share4(EPS)of$3.06,representing 22 p